About Macumira

Welcome to a New Era in Dry AMD Treatment

MacuMira stands at the forefront of global medical innovation, delivering unique, noninvasive treatment proven to improve visual function in dry AMD patients with safety and precision. 

At MacuMira, we channel a deep sense of purpose into our groundbreaking work. We craft medical technology that gives eye care professionals a proven tool to make meaningful changes in patients’ lives. We are inspired to create a brighter future for people around the globe living with dry AMD.

Learn More

Our Mission

To improve the vision and quality of life of the more than 400 million people around the world living with dry AMD and make MacuMira the standard of care for this disease.

The History of Microcurrent

Microcurrent therapy originated in the mid-20th century and emerged as a groundbreaking approach in medical treatment thanks to its ability to mimic the body’s naturally occurring electrical impulses. 

These subtle, low-level currents play a critical role in cellular activity, aiding in repair and regeneration. Early research (Assimacopoulos 1968; Wolcott et al. 1969) uncovered its potential in accelerating wound healing and promoting tissue repair by enhancing cellular communication and stimulating the production of key components such as ATP, the energy currency of cells. 

Through its precise replication of these mini-currents, microcurrent therapy has become a trusted, noninvasive technology, offering safe and effective support for cellular rejuvenation while reinforcing the body’s natural healing mechanisms.

MacuMira uses a unique, patented waveform controlled by sophisticated coding to deliver safe, effective retinal rejuvenation that can improve vision in patients living with dry AMD.